mTOR signaling is upregulated in many cancers, and the mTOR kinase central to the pathway has been a successful target of other cancer treatments, including in the treatment of subependymal giant cell astrocytomas (SEGAs) in another Ras pathway disorder, tuberous sclerosis complex (TSC) [48]. This evidence concerns the gene MTOR and cancer.